PerkinElmer

JULY 13, 2020

The complex relationship between a virus and its host is one of the hottest topics in science right now, and has been given considerable attention in recent weeks as a result of the race to understand the virus that causes COVID-19 and its potential vulnerabilities.

RNA 52

RNA Virus Laboratories Science 52

Drug Target Review

APRIL 5, 2024

She brings nearly two decades of experience in the pharmaceutical industry, and deep expertise in early drug discovery, antibody engineering (bispecifics), stable cell line development, and project management. The first concern is microbial contamination. CDMOs must routinely test throughout CLD to ensure cell cultures are free of microbes.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. President and Chief Executive Officer of Tonix Pharmaceuticals.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 31, 2020

He also previously served as Global CMO at Taiho Pharmaceutical Company, Ltd. He also held roles at Onyx Pharmaceuticals, Millennium Pharmaceuticals, Roche and Bristol-Myers Squibb. She most recently served as senior Medical Director at Ferring Pharmaceuticals in Copenhagen. and CMO for Taiho Oncology, Inc.

Engineering 52

Engineering Pharmaceuticals Clinical Development Virus 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic. Reliable, high-quality testing is essential to help healthcare systems overcome this pandemic.

Clinical Trials 52

Clinical Trials Virus Trials Treatment 52

The Pharma Data

OCTOBER 19, 2020

Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors. SOUTH SAN FRANCISCO, Calif., 20, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences , Inc.

Virus 52

Virus Pharmaceuticals Disease Science 52

Drug Target Review

DECEMBER 5, 2024

Challenges of viral capsids in gene therapy efficiency A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self-amplify.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

SEPTEMBER 3, 2020

S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2 virus. Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, Mortalities were absent in vaccinated animals.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

The Pharma Data

DECEMBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

The Pharma Data

AUGUST 31, 2020

About the cobas HIV-1/HIV-2 Qualitative Test cobas HIV-1/HIV-2 Qualitative for use on the cobas 6800/8800 Systems is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) RNA in human serum and plasma. . Reviewed June 8, 2020.

FDA Approval 52

FDA Approval FDA Virus Disease 52

The Pharma Data

DECEMBER 11, 2020

Find out below how Thermo Fisher Scientific and the University of Oxford are working together to combat the Covid-19 pandemic and discover how pharmaceutical logistics companies are preparing for vaccine distribution. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.

Vaccine 52

Vaccine Immune Response Pharma Companies Virus 52

The Pharma Data

OCTOBER 6, 2021

Data from the early-stage study suggest that an antiviral compound prevents the interaction between two viral proteins (NS3 and NS4B) that play an important role in the replication process of a virus, thereby stopping the ability of the virus to reproduce. Janssen is now moving its dengue program into clinical development.

Virus 52

Virus Clinical Development Science Disease 52

The Pharma Data

DECEMBER 9, 2020

NEW YORK–( BUSINESS WIRE )– Rocket Pharmaceuticals, Inc. About Rocket Pharmaceuticals, Inc. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. 10, 2020 04:32 UTC. Forward-looking Statements.

Pharmaceuticals 40

Pharmaceuticals Clinical Trials Therapies Trials 40

New Drug Approvals

SEPTEMBER 6, 2024

US10071079, Example 15 Ref WO2018005586 [link] The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to TLR modulation, such as inflammatory and autoimmune diseases, and methods of inhibiting the activity of TLRs in a mammal.

RNA 62

RNA Clinical Trials Disease DNA 62

The Pharma Data

DECEMBER 18, 2020

18, 2020 — Recipients of kidneys from donors infected with hepatitis C virus (HCV) have similar kidney allograft function and probability of rejection in the first year after transplantation as those who receive kidneys from donors without HCV infection, according to a study published online Dec. Professional. FRIDAY, Dec.

Virus 52

Virus Science Pharmaceuticals Disease 52

The Pharma Data

OCTOBER 30, 2020

Regeneron Pharmaceuticals, Inc. About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. ” To solve those problems, Varadarajan collaborated with Xinli Liu, professor of pharmaceutics at the UH College of Pharmacy, and an expert in nanoparticle delivery. . Breathe in, exhale. But now, we’re one step closer.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

SEPTEMBER 1, 2020

This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

DECEMBER 22, 2020

We will leverage this financing to accelerate collaborative research with pharmaceutical manufacturers and internal research using its own pipeline. We will especially do our best to provide therapeutic pharmaceuticals to treat COVID-19 through collaborative research with Kitasato University and Kao Corporation.”.

Engineering 52

Engineering Pharmaceuticals Drugs Protein Production 52

The Pharma Data

JANUARY 24, 2021

Theralase ® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses. ” About Theralase® Technologies Inc.

Pharmaceutical Companies 52

Pharmaceutical Companies Virus Clinical Research Pharmaceuticals 52

The Pharma Data

FEBRUARY 24, 2022

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID?19)

Vaccine 52

Vaccine Virus Government Disease 52

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

APRIL 15, 2022

These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group. The neutralizing GMT against the wild-type virus was 2153 (after three doses), compared to 335 after two doses. Source link: [link].

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

AUGUST 21, 2020

When COVID-19 began to emerge – first in Asia, then in Europe – she could see that its relative ease transmitting from person to person, along with the lack of tests and preventions or treatments for infection, made the virus a credible threat to humanity. Source link.

Virus 52

Virus Small Molecule Licensing Licensing 52

The Pharma Data

JANUARY 8, 2021

For example, pharmaceutical regulatory bodies are working tirelessly to fast track the approval of vaccines to treat Covid-19, doctors are now better prepared to handle patients with coronavirus and testing is becoming faster and more accessible. The New Year brings new hope as UK regulators approve Oxford vaccine for emergency use.

Vaccine 52

Vaccine Government Doctors Pharmaceuticals 52

The Pharma Data

MAY 19, 2023

HIGH SCHOOL SCIENTISTS AND ENGINEERS WIN NEARLY $9 MILLION AT THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR 2023 Regeneron Pharmaceuticals, Inc. This allowed him to identify the mutations in the virus that likely made it more infectious as well as other mutations that could make it resistant to antibiotics.

Engineering 52

Engineering International Science Virus 52

The Pharma Data

JANUARY 3, 2021

04, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that its subsidiary, InspirMed Inc., SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Disease 52

The Pharma Data

MARCH 26, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Medicines Agency (EMA) approved storage of COMIRNATY® at -25°C to -15°C for a total of two weeks based on data showing the stability at these temperatures in standard pharmaceutical freezers.

Vaccine 52

Vaccine Doctors Pharmacy FDA 52

The Pharma Data

DECEMBER 17, 2020

17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y. , NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

APRIL 3, 2021

Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “The

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

AUGUST 21, 2020

Bill Anderson, chief executive officer of Roche Pharmaceuticals, said: “We are excited about the potential for one medicine to serve both as a treatment for those infected as well as protection for people exposed to the virus. REGN -COV2 could be a critical line of defense against the Covid-19 pandemic.”.

Vaccine 52

Vaccine Clinical Trials Pharmacy Virus 52

The Pharma Data

OCTOBER 6, 2021

A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. Source link: [link].

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

DECEMBER 28, 2020

is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife Pharma Inc.

Licensing 52

Licensing Licensing Compliance Virus 52

The Pharma Data

FEBRUARY 22, 2021

Bayer AG’s decision to join forces with CureVac and help produce the vaccine is another crucial step in the fight against the virus,” said State Premier Laschet. The pharmaceutical and biotechnology site in Wuppertal offers ideal conditions for the high-tech, complex process of vaccine production.”.

Vaccine 40

Vaccine Production Virus Pharmaceuticals 40

The Pharma Data

JANUARY 19, 2021

–( BUSINESS WIRE )– Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 About Syros Pharmaceuticals. 20, 2021 03:41 UTC.

Small Molecule 52

Small Molecule Clinical Trials Pharmaceuticals Virus 52

The Pharma Data

DECEMBER 20, 2020

We are excited to work with BetterLife to build out our product line and conduct further R&D to develop an exciting IP portfolio surrounding LSD based pharmaceutical treatments,” said Transcend CEO, Justin Kirkland. Both companies have similar values and complementary strengths, which make this a strong corporate and cultural fit.”.

Production 52

Production Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 20, 2021

On January 19th , LumiraDx became the first foreign company to receive approval for its SARS-CoV-2 Antigen Test from Japan’s Pharmaceutical and Medical Devices Agency (PMDA). It has not been authorized for use to detect any other viruses or pathogens. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Virus 52

Virus Hospitals FDA Pharmaceuticals 52